Clinical trials: Antipsychotic Agents
Dementia
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a…
- Trial name
- NCT00197834
- Testing
- Depakote
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hearthstone Alzheimer Care
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Bipolar I Disorder
Risperdal Consta for Bipolar Disorder
We recruited 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who were about to initiate or switch their current antipsychotic agent.
- Trial name
- NCT00177164
- Testing
- Injectable Risperidone (Consta) or oral antipsychotic
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2_3Y (NCT02526030)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Weight Loss, Diabetes Mellitus, Type 2
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications.
- Conditions
- Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
- Trial name
- STRIDE (NCT00790517)
- Testing
- Premier Lifestyle Intervention with DASH Diet
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Schizophrenia
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or…
- Trial name
- NeSSy (NCT01164059)
- Testing
- Olanzapine, Flupentixol, Quetiapine
- Where
- 18 sites in Germany
- Volunteers
- 149 people
- Sponsor
- University of Bremen
Schizophrenia
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
We wanted to compare dopamine D2 receptor activity, brain structure, brain function, sensory gating and cognition in neuroleptic-naive schizophrenic patients and matched healthy controls.
- Trial name
- NCT00206960
- Testing
- zuclopenthixol, risperidone
- Where
- 6 sites in Denmark
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Schizophrenia
The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study.
- Trial name
- NCT03080194
- Testing
- paliperidone palmitate, control group
- Volunteers
- 150 people
- Sponsor
- Maosheng Fang
Antipsychotic Induced Weight Gain
: EFFECT OF PROBIOTIC SUPPLEMENTATION ON ATYPICAL ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS ATTENDING PSYCHIATRIC CLINICS AT AINSHAMS UNIVERSITY HOSPITALS (A RANDOMIZED CONTROLLED TRIAL)
the goal of the study is to improve the quality of life of patients on antipsychotic medications and increase the rate of compliance to treatment.
- Trial name
- NCT06936137
- Testing
- lactobacillus LS
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Schizophrenia
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
The purpose of this study is to: To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory…
- Trial name
- NCT00161031
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
D-serine Monotherapy for Schizophrenia
A first generation of clinical studies, performed during the last decade, demonstrates that adjuvant treatment with compounds that enhance NMDAR-mediated neurotransmission due to their agonistic activity at the NMDAR-associated…
- Trial name
- NCT00816894
- Testing
- D-serine, Olanzapine
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Herzog Hospital
Colon Cancer Stage III
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis…
- Trial name
- NCT05433402
- Testing
- ChlorproMAZINE 50 MG, Control
- Where
- Egypt
- Sponsor
- Sadat City University
Schizophrenia
Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects
This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.
- Trial name
- NCT00815854
- Testing
- Folic Acid
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Michigan
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia
- Trial name
- TAAS (NCT02040883)
- Testing
- Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole, Tandospirone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qingyun Yin
Schizophrenia, Schizophrenia Relapse
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
This prospective longitudinal cohort study will follow patients with schizophrenia who are treated with second generation long-acting injectable antipsychotic medications (LAIs) for 48 weeks to determine the risk of psychotic…
- Trial name
- NCT05473741
- Testing
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
The Effects of Aripiprazole on Patients With Metabolic Syndrome
The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- NCT00224822
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- New Mexico VA Healthcare System